Arrestin pathways as drug targets
- PMID: 23764065
- DOI: 10.1016/B978-0-12-394440-5.00018-8
Arrestin pathways as drug targets
Abstract
Our growing appreciation of the pluridimensionality of G protein-coupled receptor (GPCR) efficacy, coupled with the phenomenon of orthosteric ligand "bias," offers the prospect of drugs that selectively modulate different aspects of GPCR function for therapeutic benefit. As the best-studied non-G protein effectors, arrestins have been shown to mediate a wide range of GPCR signals, and arrestin pathway-selective ligands have been identified for several receptors. When viewed from the perspective of short term in vitro assays, such "biased" agonists appear to activate a subset of the response profile produced by a conventional agonist. Yet, when examined in vivo, the limited data available suggest that biased ligand effects can diverge from their conventional counterparts in ways that cannot be predicted from their in vitro efficacy profile. While some widely conserved arrestin-regulated biological processes are becoming apparent, what is lacking at present is a rational framework for relating the in vitro efficacy of a "biased" agonist to its in vivo actions that will aid drug discovery programs in identifying "biased" ligands with the desired biological effects.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Emergent biological properties of arrestin pathway-selective biased agonism.J Recept Signal Transduct Res. 2013 Jun;33(3):153-61. doi: 10.3109/10799893.2013.769004. Epub 2013 Feb 28. J Recept Signal Transduct Res. 2013. PMID: 23448506
-
Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.Methods Enzymol. 2013;522:229-62. doi: 10.1016/B978-0-12-407865-9.00013-3. Methods Enzymol. 2013. PMID: 23374189
-
Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.Mol Pharmacol. 2015 Sep;88(3):579-88. doi: 10.1124/mol.115.099630. Epub 2015 Jul 1. Mol Pharmacol. 2015. PMID: 26134495 Free PMC article. Review.
-
Refining efficacy: exploiting functional selectivity for drug discovery.Adv Pharmacol. 2011;62:79-107. doi: 10.1016/B978-0-12-385952-5.00009-9. Adv Pharmacol. 2011. PMID: 21907907 Review.
-
Beta-arrestin-biased ligands at seven-transmembrane receptors.Trends Pharmacol Sci. 2007 Aug;28(8):416-22. doi: 10.1016/j.tips.2007.06.006. Epub 2007 Jul 20. Trends Pharmacol Sci. 2007. PMID: 17644195 Review.
Cited by
-
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.Mol Endocrinol. 2014 Mar;28(3):281-94. doi: 10.1210/me.2013-1314. Epub 2014 Jan 16. Mol Endocrinol. 2014. PMID: 24433041 Free PMC article. Review.
-
Down-regulation of β-arrestin2 promotes tumour invasion and indicates poor prognosis of hepatocellular carcinoma.Sci Rep. 2016 Oct 19;6:35609. doi: 10.1038/srep35609. Sci Rep. 2016. PMID: 27759077 Free PMC article.
-
Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis.Int J Biochem Cell Biol. 2016 Aug;77(Pt B):240-50. doi: 10.1016/j.biocel.2016.04.016. Epub 2016 May 7. Int J Biochem Cell Biol. 2016. PMID: 27167177 Free PMC article. Review.
-
The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.Pharmacol Rev. 2017 Jul;69(3):256-297. doi: 10.1124/pr.116.013367. Pharmacol Rev. 2017. PMID: 28626043 Free PMC article. Review.
-
Positive and Negative Cross-Talk between Lysophosphatidic Acid Receptor 1, Free Fatty Acid Receptor 4, and Epidermal Growth Factor Receptor in Human Prostate Cancer Cells.J Pharmacol Exp Ther. 2016 Oct;359(1):124-33. doi: 10.1124/jpet.116.233379. Epub 2016 Jul 29. J Pharmacol Exp Ther. 2016. PMID: 27474750 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
